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Abstract
Background: The entry of HIV into its target cells is facilitated by the prior binding to the cell
surface molecule CD4 and a secondary coreceptor, mostly the chemokine receptors CCR5 or
CXCR4. In early infection CCR5-using viruses (R5 viruses) are mostly dominant while a receptor
switch towards CXCR4 occurs in about 50% of the infected individuals (X4 viruses) which is
associated with a progression of the disease. There are many hypotheses regarding the underlying
dynamics without yet a conclusive understanding.
Results: While it is difficult to isolate key factors in vivo we have developed a minimal in silico
model based on the approaches of Nowak and May to investigate the conditions under which the
receptor switch occurs. The model allows to investigate the evolution of viral strains within a
probabilistic framework along the three stages of disease from primary and latent infection to the
onset of AIDS with a a sudden increase in viral load which goes along with the impairment of the
immune response. The model is specifically applied to investigate the evolution of the viral
quasispecies in terms of R5 and X4 viruses which directly translates into the composition of viral
load and consequently the question of the coreceptor switch.
Conclusion: The model can explain the coreceptor switch as a result of a dynamical change in the
underlying environmental conditions in the host. The emergence of X4 strains does not necessarily
result in the dominance of X4 viruses in viral load which is more likely to occur in the model after
some time of chronic infection. A better understanding of the conditions leading to the coreceptor
switch is especially of interest as CCR5 blockers have recently been licensed as drugs which
suppress R5 viruses but do not seem to necessarily induce a coreceptor switch.
Background
Although many studies aim to understand the evolution
of the human immunodeficiency virus (HIV) in its host
[1-3] there are still a lot of open questions related to the
mechanisms driving the intra-host dynamics. One of
these puzzles is associated with the HIV coreceptor
switch [4]: To facilitate cell entry and subsequent
replication HIV binds to the cell surface molecule CD4
as well as a chemokine coreceptor, most commonly the
CCR5 or CXCR4 coreceptors. In most patients viruses
that use the CCR5 coreceptor (R5 viruses) dominate in
early stages of disease. This preference changes however
in about 50% of patients during the course of disease
towards viruses using the CXCR4 coreceptor (X4
viruses). This switch in coreceptor usage is associated
with a worsened prognosis which makes a better
understanding of the switch dynamics of direct clinical
importance. At the same time there are several
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standing of the underlying processes in terms of
empirical evidence or model support. The transmission
mutation hypothesis [4] assumes that R5 viruses are
favoured in transmission and are in consequence more
often found in early infection. X4 viruses with higher
fitness can emerge from R5 viruses via intermediate
mutants of lower fitness which will finally become
dominant [4]. While there is some evidence for a fitness
loss of intermediate mutants [5-7], this hypothesis
strongly relies on the assumption that X4 viruses can
hardly be transmitted in infectious doses as these would
otherwise immediately become dominant due to their
assumed selectional advantages in the host. There might
be some strain selection during transmission but there is
evidence that both R5 and X4 strains can be transmitted
in infectious doses, however, with X4 viruses seemingly
having a selectional disadvantage thereafter [8,9]. The
effective replication rate of X4 viruses exceeds R5
replication in some in vitro assays [10], there is, however,
no conclusive picture of the in vivo situation with
different environmental constraints [4,11]. Taken this
together [4,12-14], it is highly questionable whether a
fragile setting relying solely on the transmission muta-
tion hypothesis adequately describes the major pro-
cesses in place or robustly represents the observed
dynamics.
An alternative and less fragile hypothesis assumes that
environmental conditions in the host change during the
course of disease in favour of X4 viruses. Such changes
may be the consequence of immune pressure or the
availability of adequate target cells for replication in
terms of (co-)receptor expression or replication effi-
ciency by stage of cell development (naive/memory
cells) [4,15]. In a recent study Sguanci and coworkers
[16] investigate the changing environment by assuming
that the susceptibility of target cells (or infectivity of
viruses) increases in favour of X4 cells as soon as these
emerge in an auto-catalytic fashion, however, staying
with the assumption that the initial infection is with R5
virus only. Earlier work by Wodarz et al. [17] and
Callaway et al. [18] allows more realistically for a mixed
infection and investigates how the shift in target cells
and HIV specific T cells can dynamically induce a shift
from R5 to X4 viruses. In a similar fashion, Ribeiro et al.
investigate how the coreceptor switch can be facilitated
due to preferential replication of X4 and R5 viruses in
naive and memory T cells, respectively, with differences
in efficiency of viral reproduction [15]. These
approaches support the hypothesis of environmental
change as a driving force to the coreceptor switch but do
not consider the stochastic nature of virus evolution
and the emergence of new strains and viral diversity
which have been associated with the coreceptor switch.
While the relative importance of the above hypotheses
for the coreceptor switch can ultimately only be
answered experimentally we will here focus on the
more robust hypothesis of environmental change for
further analysis. We want to identify key processes
resulting in the observed phenomenon by a restriction
to a minimal model representing the dynamics of the
immune system and HIV [19]. Therefore, we develop an
approach based on the well studied model of Nowak
and May [20] that allows to study the dynamical
processes associated with the HIV coreceptor switch in
combination with viral evolution. While we do not go
yet into the details of cellular subpopulations whose
roles are empirically still under debate we rather take
advantage of the relative simplicity of the model to
study the effects of the stochastic nature of HIV
evolution neglected in the models outlined above. The
stochastic framework will allow to analyse the distribu-
tion of evolutionary pathways associated with the
coreceptor switch as well as survival times in a more
systematic way.
It has specifically become of major importance to
understand the processes leading to the dominance of
X4 viruses since new drugs have been licensed that block
the CCR5 receptor [12,21-23] and in consequence can
shift the selective advantage towards X4 viruses [24],
although not necessarily inducing a coreceptor switch.
Considering the association between X4 viruses and a
worsened prognosis [4,25] it is of vital importance to
understand whether X4 can only flourish in the environ-
ment of a patient weakened by side effects of a chronic
infection or whether X4 viruses themselves destabilise the
patient and cause the worsened prognosis [13].
Results and Discussion
The Model
Following the ansatz of Nowak and May [20,26] we
study the time evolution of viral load vi of a set of n
strains (i Œ {1, ...,n}). These are controlled by a specific
immune response with strength xi and as well as a cross-
reactive immune response with strength z.T h e i rt i m e
evolution is determined by the following set of
equations:
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with variables and parameters as summarised in table 1.
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diminished by the specific and cross-reactive immune
response at a rate -pixi - qiz. Vice versa, a specific immune
response is stimulated by each strain as is the cross-
reactive immunity by the total viral load. Immune
responses decay at a rate b and further at a rate
proportional to the viral load which is to account for
the fact that HIV infected T helper cells are depleted (and
in consequence impair the immune response mediated
by other T and B cells). Among the 2
n possible
equilibrium solutions of a set of equations (1) for n
strains at most one is stable [20], that is, for any number
of strains the viral load either diverges or converges to a
well defined equilibrium viral load. Strains are distin-
guished by their sensitivity towards the specific immune
response, i.e. several related genomic sequences might
represent the same epitope and consequently correspond
to one strain in the model. The model does not yet
address the question of different immune cell popula-
tions as for example CD4 vs. CD8 cells, naive vs.
memory cells or resting vs. replicating cells. The
distinction between xi and z takes only into account
that there is a strain specific and an unspecific
component of the immune response. The latter can be
a composition of the response towards conserved parts
of the virus, of cross-reactivity from earlier specific
immune responses or innate immunity. Bare of any
strain-specific responsiveness, z is a measure for the
general activation of the immune system going along
with an overall turnover of CD4 cells (irrespective of
their specificity) seen in HIV infections [27,28].
TofocusontheevolutionofR5andX4virusesinapatient
we distinguish only between two parameter sets corre-
sponding to either type of virus as listed in table 2. The
values of initial viral growth rates are estimated from
[29,30]. However, viral growth rates or more generally
viral fitness as the balance between viral replication and
decay is not an intrinsic feature of the virus but is only
well defined in the context of the viruses environmental
conditions. Differences in viral fitness may therefore arise
among viruses and over time with a change of environ-
mentalconditionssuchastheavailabilityoftargetcellsor
the strength of an immune response. Here, we assume
that X4 viruses are better recognised by the specific
immune response than R5 viruses [31] and increase their
replication rate proportional to the stimulation and
activation of the immune system [15,27,28] represented
b yt h ec r o s s - r e a c t i v ei m m u n i t yz. While the cumulative
immune activationz will likely impact on both R5 andX4
viral replication [15,32] we are only interested in the
increase of X4 replication over R5 replication and there-
fore keep the R5 replication rate fixed. The cumulative
immune activation z increases slightly during the course
of disease and breaks only down with the collapse of the
immune system at the onset of AIDS. The chosen
parameter set corresponds to a situation in which the
viral load can initially be controlled by the immune
response,i.e. a situation in which limitations in target cell
supplies or other saturation phenomena do not have to
be taken into account. The model’s dynamics is robust
with respect to the choice of further parameters as long as
they correspond to the model’s regime of HIV-like
dynamics (cf. equation (4)).
Table 1: Variables and parameters in equations (1)
vi viral load from strain i
xi specific immune response to strain i
z cross reactive immune response
ri growth rate of virus i
pi, qi effect of specific and cross reactive immune response on strain i
ci, ki growth of specific and cross reactive immune response induced
by and directed against strain i
b natural decay of the immune response
ui decay of immune response induced by strain i.
Table 2: Parameter settings
parameter R5 virus X4 virus
number of strains n
R5 n
X4
viral growth rate ri r
(2d
-1)
r(1 + az)
((2 + z)d
-1)
effect of specific immune response pi p
R5
(2d
-1)
p
X4 >p
R5
(20d
-1)
effect of cross-reactive immunity qi q
(1.86d
-1)
stimulation of specific and
cross-reactive immunity ci, ki
c, k
(0.1d
-1VL
-1)
natural and virus induced depletion of
immune response b, ui
b, u
(0.02d
-1,0 . 1 d
-1VL
-1)
probability to generate a new strain
pm per day and viral load
1
2 pm
(0.005d
-1VL
-1)
Parameter settings for R5 and X4 viruses, the values chosen in the
s i m u l a t i o n sa r eg i v e ni nb r a c k e t si nunits per day (d) and viral load (VL),
due to the close genetic neighbourhood of R5 and X4 viruses it is
assumed that both mutants occur with the same probability 1
2 pm from
the total viral population irrespective of its composition. Where direct
biological interpretation is possible parameters have been chosen
following [29,30], remaining degrees of freedom have been fixed to
account for the appropriate dynamical regime defined by equation (4).
Note that the growth rate of X4v i r u s e si sa s s u m e dt oi n c r e a s e
proportional to the immune activation measured by the cross reactive
immunity z with a =0 . 5 .
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and a strain of X4 virus and evolves according to
equations (1). A new mutant arises at a hazard rate
pmv,i . e .a te a c hi n t e g r a t i o ns t e po fl e n g t hdt with
probability 1−≈
− ep v d t
pv d t
m
m . In the current setting, X4
and R5 mutants are assumed to arise with equal
probability irrespective of the composition of the viral
load due to the close genetic neighbourhood of these
viral subtypes [33,34] (for further discussion cf. Addi-
tional file 1, Figure S1). After the emergence of each new
mutant the system reaches a new equilibrium with n
R5
R5 virus strains and n
X4 X4 virus strains and viral load
vn n v n n v n n
br nX pR nR pX
cpR
RX RRX XRX (, ) (, ) (, )
()
54 554 454
45 54
5
=+
=
+
p pX nX pR ru k q r nR pX ru kq 44 5 5 4 −− − −− (( ) ) ( )
.
α
(2)
The system is stable, i.e. there is a stable equilibrium
solution only if
1. ru <kq, i.e. the viral load is fully controlled by the
cross reactive immune response z alone or
2.
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t h a ti s ,o n l ya sl o n ga st h en u m b e r so fR 5a n dX 4
virus strains do not exceed the critical numbers given
by condition (3) the immune system can control the
infection.
We are specifically interested in dynamical regimes of the
model which remain only stable for finite numbers of R5
and X4 virus strains (as opposed to case 1.) but do not
show immediate divergence (cp
R5 -( ru - kq)>0 )w h i c h
corresponds to
kq ru kq cp
R <<+
5. (4)
The first inequality in (4) implies that the cross-reactive
immune response cannot fully control the viral infection
as can be seen from equation (2). This means that each
viral strain needs to be suppressed both by a specific and
a cross-reactive immune response. The second inequality
implies that the immune system can control only a
limited number of strains, i.e. the limitations of the
cross-reactive immune response can be compensated by
the specific immune response if the critical number of
strains given by equation (3) is not exceeded. As soon as
this number of strains is exceeded this will lead to an
uncontrolled increase in viral load in the model
corresponding to the onset of AIDS in the patient [20].
The detailed dynamics in this regime are not longer
described by equations (1) as saturation effects have to
be considered due to limited resources.
The emergence of viral strains in a patient that
accumulate to the critical number at the onset of AIDS
can also be understood in a probabilistic framework in
order to study survival distributions. Therefore we derive
the probability P(n
R5, n
X4, t) that a patient harbours n
R5
strains of R5v i r u sa n dn
X4 strains of X4v i r u sa tt i m et.I f
the viral load equilibrates much faster after the emer-
gence of a new mutant than the next mutant arises we
can assume that new mutants will approximately arise at
a rate proportional to the equilibrium viral load v(n
R5,
n
X4). In the regime where nn nn n
R
c
RX
c
XR 55 44 5 << ,( )
and v(n
R5, n
X4)< vmax the evolution of the number of
viral strains is then described by a Markov process with
the master equation [35]
∂
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For those states in which the critical number of strains
given by equation (3) or a maximal viral load vmax is
exceeded, i.e. at the onset of AIDS, the last term in
equation (5) is defined to vanish making these states
absorbing states of the Markov process. vmax limits the
diverging viral load v(n
R5, n
X4) as the total viral load in
the patient is limited. The distribution of times until
absorption, i.e. the survival distributions, are described
by phase type distributions [36].
T h ec o u r s eo fd i s e a s e
First insight into the evolutionary dynamics of R5 and X4
viruses can be gained by investigating the time course of
viral load attributed to each subtype in the model. Such
a typical course of disease after a mixed infection with R5
and X4 viruses in the model is shown in Fig. 1.
The system shows a period of low viral load after the
initial phase of disease with is interspersed with small
outbreaks when a new viral mutant occurs - until
eventually the viral load rises again. The system shows
a quasi-stable behaviour as long as inequality (3) can be
fulfilled for a non-zero but limited number of strains, i.e.
if inequality (4) holds.
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early stages of disease as them o d e la s s u m e st h a tt h e y
a r em o r es t r o n g l ys u p p r e s s e db yt h es p e c i f i ci m m u n e
response than R5 viruses (p
X4 > p
R5) [31] while having
initially identical growth rates [11]. On the other hand
the X4 replication rate in the model increases propor-
tional to the overall activation of the immune system
represented by the cross-reactive immune response.
This shifts fitness advantages from R5 viruses to X4
viruses resulting in the phenomenology of a coreceptor
switch.
The model captures the association between ongoing
immune activation and the apparent shift in evolu-
tionary advantages from R5 to X4 viruses during an HIV
infection. There is however still controversy about the
mechanisms underlying this association. Earlier assump-
tions about a shift in target cells favouring X4 over R5
viruses [4] are now questioned [37]. An alternative
hypothesis links the efficiency of viral production to the
division rate of target cells [15]. With the differential
increase in target cell division rates during chronic
infection [32] viral replication rates are differentially
increased which eventually shifts the selectional advan-
tage from R5 viruses to X4 viruses [15,27,28]. Another
interpretation of the model equations is that X4 viruses
experience a stronger specific immune response than R5
viruses but that they face a reduced cross-reactive
immune response. In consequence X4 viruses will be
more difficult to control as the number of strains grows.
Any of these hypotheses allows for a dynamical change
in environmental conditions in the host that become
more favourable for X4 viruses after chronic infection
while selection is in favour of R5 viruses in early stages
of disease. Although, there is some evidence
[4,11,15,31,32] in accordance with the model’s assump-
tions on parameter settings it is difficult to get
conclusive results from currently available empirical
data. Many studies with one or only a few HIV or SIV
cases point in different directions [5-7,38]: Any com-
parative measurement of growth rates and the effect of
an immune response among strains in vivo assesses
quantities derived from a large variety of underlying
processes that might vary among cases. Therefore, a
more conclusive picture can only be expected with the
integration of more data describing the interactions
between HIV and the immune system in many patients.
The observation that some viral strains may be present
in a patient for a long time before they appear in
detectable numbers favours the idea of a dynamical
change in the environmental conditions in favour of X4
viruses [39,40] at a higher level of abstraction. Reflecting
these findings, the current model provides a coarse
grained picture of possible scenarios for environmental
shifts in the patient for further investigation. While
details of these dynamics will have to be addressed
within a refined model the current model has the
advantage to be accessible to further analysis of the basic
underlying stochastic processes as demonstrated in the
following sections.
The routes of evolution
The probabilistic framework complementarily allows to
study the probability to find a setting with n
R5 R5 strains
and n
X4 X4 strains in a patient at any time during the
course of disease - including the probability to have
reached the final stage of disease, i.e. having exceeded
the critical number of strains.
Fig. 2 shows that a patient is most likely to be found
either with a few strains or inas i t u a t i o ni nw h i c ht h e
final stage of disease has already been reached. This is
due to the fact that the viral load and in consequence the
probability to generate new mutants increases with a
growing burden of viral strains. As a result the mean
residence time with a given number of strains
λnn
RX
pmvn R nX
54 1
54 , (,)
= will decrease as the number of
strains grows, i.e. the course of disease speeds up with
the accumulation of viral strains. The distribution of
strain compositions shown in Fig. 2 is asymmetric with
respect to the numbers of R5 and X4 strains in the
presence of a moderate number of strains, i.e. in a stage
of disease that is not yet progressed. A moderate number
of strains will not result in strong stimulation of the
immune system and X4 replication and viral load remain
at a low level compared to the contribution of R5 strains.
Figure 1
T h ec o u r s eo fd i s e a s ei nt h em o d e l . Viral load of R5
viruses(blue)andX4viruses(red)inasimulationofthemodel
described by equations (1) and parameters as in table 2. The
viral load is given in arbitrary units of viral load (VL).
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(page number not for citation purposes)X4 strains will consequently not drive the course of
disease as much ahead as R5 strains in early stages of
disease. Therefore the model predicts that non-progres-
sors may even have more X4 strains than R5 strains
without experiencing a coreceptor switch. The intricate
dependency of the coreceptor switch on the numbers
and composition of strains is analysed in detail in the
following section.
The coreceptor switch
The coreceptor switch is a phenomenological observation
for which a corresponding process has to be characterised
in our model. As the simulations start with a dominance
of R5 viruses due to the bias in immune recognition (i.e.
p
X4 > p
R5) we define that a coreceptor switch has occurred
if the viral load is dominated by X4 viruses at the onset of
AIDS which is determined in the model by either
exceeding a viral load vmax or the critical numbers of
strains n
R5 and n
X4 (cf. Fig. 2). From
vX
vR
c
pR
nR kr
c
pX
nX kr
4
5
5
5
4
4
=
+
−
α
α
(6)
it can be seen that it depends on the number and
composition of viral strains in the system which type of
virus dominates, i.e. when the trade-off between replica-
tion rate and sensitivity to the immune response favours
X4 viruses. X4 viral load dominates in a patient who has
not yet reached the terminal stage of disease if
n
pX nR
pR kr
c
nR
X4
45
5 2 5
>
+
α , (7)
which corresponds to the area shaded in red in Fig. 3. In
early infection X4 strains do not impose a high viral load
and the number of X4 strains required to dominate the
viral population in the presence of R5 viruses is usually
not found in a patient. This picture changes in late
infection where a smaller fraction of X4 strains among all
strains can be sufficient for dominance in in viral load.
This can be seen in Fig. 3 which shows graphically what
strain composition leads to a dominance in X4 viral load
(red shaded area) and when the system is destabilised
indicating the onset of AIDS (grey shaded area). The
saturation behaviour of equation (7) implies that
dominance of X4 viruses in viral load can be attained
with a minority of X4 strains as soon as
nn
c
kr
pp
XR X R 45 4 5
2
,( ) . >−
α
(8)
Figure 2
The distribution of strains. The probability to find n
R5 R5
strains and n
X4 X4 strains in a patient at 1200 days since
infection in the model with parameters as in table 2 and
vmax = 500 units of viral load, the final stage of disease
(absorbing state) is marked by the accumulation of
probability density at the diagonal border.
Figure 3
X4 dominance and the onset of AIDS. The figure shows
how the dominance of X4 viral load and the onset of AIDS
depends on the number of X4 and R5 strains present in the
system according to equations (3) and (7), for parameters cf.
table 2.
BMC Evolutionary Biology 2009, 9:274 http://www.biomedcentral.com/1471-2148/9/274
Page 6 of 11
(page number not for citation purposes)Note that this situation is only observed in the
latent phase defined by equation (3) if X4 viruses
gain sufficiently fast replicative fitness, i.e.
α >
−− () ( ) ru kq pX pR
krpR
45
5 .
Within the model the occurrence of a coreceptor switch
depends on the probabilistically chosen evolutionary
path in the patient (cf. Fig. 2) - i.e. whether a path is
chosen that leads directly to destabilisation and AIDS or
whether the final stage is reached after a switch in
coreceptor usage. The probabilities for either choice are
shown in Fig. 4. It shows that for any newly infected
patient the probabilities of eventually reaching the final
stage of disease with dominance of R5 viruses or X4
viruses are of the same order of magnitude with the
parameter set chosen in in table 2. Dominance of X4
viruses is only possible with a certain amount of strains
and immune activation being established and is there-
fore associated with an increased number of strains and a
progressed stage of disease.
The results from the probabilistic approach considering
equilibrium viral load according to equation (5) are
compared with survival curves sampled from simula-
tions of equations (1) based on the actual viral load. The
good agreement shows that the flow of mutants is
strongly determined by the equilibrium viral load (cf.
Additional file 2 and 3, Figure S2 and S3).
As the average time to the onset of AIDS as well as the
mean residence times in a given stage decrease with the
accumulation of mutant strains (cf. equation (16))
patients with dominance in X4 viral load have a
worsened prognosis in this respect. The higher burden
in viral load associated with the higher number of strains
leads to an accelerated progression of disease (cf.
equation (16) and Figs. 2 and 3).
Note that suppression of R5 viruses as facilitated by
coreceptor blockers [12,21-23] does not only reduce R5
viral load in the model but also diminishes the X4 viral
load due to reduced immune activation (cf. Additional
file 4, Figure S4).
Conclusion
A mechanistic assessment of the processes leading to the
coreceptor switch in HIV infected patients is difficult -
and maybe even inadequate - due to the large variability
and stochasticity of the underlying processes in vivo.
Quantities such as viral growth or clearance rates are
often only known in very specific settings without
detailed knowledge of possible hidden dependencies
from the underlying dynamical processes - and can in
consequence point in contradictory directions. The
observation that certain HIV strains may be present in
a patient for a long time before they grow to a
detectable viral load [39,40] hints however towards a
picture of a dynamical change in the environmental
conditions in the host. This holds specifically for X4
viruses [40].
The current model provides a coarse grained, probabil-
istic picture of possible dynamical scenarios of the
coreceptor switch without going yet into the details of
v i r u sr e p l i c a t i o na n di m m u n er e s p o n s e .T h i sa l l o w st o
study the basic dynamical features and conditions for a
coreceptor switch. In the model, the viral quasispecies
[41] is generated by a probabilistic process under the
pressure of the immune system. Its composition
depends on the randomly chosen evolutionary path
that may show some biases due to environmental
conditions. These include the viral replication efficien-
cies based on adequate target cells as well as constraints
of immune recognition or therapy. The answer to the
question whether a coreceptor switch has occurred is
determined by the composition of the viral quasispecies
found at the time when the host’s immune system loses
control and the viral load diverges, i.e. at the onset of
AIDS in the model system. One prediction is that the
suppression of R5 viruses in the host will not
necessarily result in an expansion of X4 viruses. The
control of R5 viruses can even delay or prevent the
emergence of considerable X4 viral load - which
Figure 4
Survival distribution and the coreceptor switch.T h e
probability to have reached the final stage of disease (black)
either with dominance in viral load of R5 viruses (blue) or X4
viruses (red) according to the master equation (5), the
survival distribution sampled from 200 simulations of
equation (1) (grey) agree well with the master equation’s
predictions i.e. giving support to the assumption of quasi-
stationary viral populations, parameters according to table 2.
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biases in the choice of the possible evolutionary paths.
This is well in accordance with the studies done for a
newly licensed drug which blocks the CCR5 receptor
[22,23,40]. The model provides a stochastic framework
to investigate R5 and X4 virus evolution in a dynamic
environment, however staying with a qualitative
description of the cellular processes. This is a strong
simplification of the complex interaction network that
interlinks HIV and the hosts immune system. The
growing knowledge about their interactions
[15,27,32,42] will be implemented within a refined
model. This should combine the advantages of this
stochastic approach with more details on the involved
immune cells populations - both with regard to their
role in the immune response and their contribution to
persistent immune activation and viral replication - to
allow for more quantitative predictions.
Methods
Virus evolution
The differential equation for the evolution of viral load
and immune response (1) have been solved numerically
with routine rk4 from the Math::RungeKutta module for
PERL. The system is initialised with one R5 viral strain
and one X4 viral strain with v
R5(0) = v
X4(0) = 1VL ,i . e .
one unit of viral load for each subtype. During each
integration step of duration dt =0 . 0 2 d an e wm u t a n t
arises with probability dt × pm × v =0 . 0 2 d ×0 . 0 1 d
-1VL
-1 ×
v proportional to the viral load v. R5a n dX4m u t a n t s
occur with equal probability.
Equation (2) can be derived from equations (1)
following [20] (chapt. 13) by assuming the stationary
case, i.e.  vxz ii == = 00 0 ,,,i . e .
rb r uv pcv q kv
rb r uv pcv q
ii j j i i i i
j
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ii j j i i i
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11
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for {vi|vi ≠ 0}. With the parameters from table 2 this
results in
rb ruv cp v kqv
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R
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R
X
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X
+− −=
+− −− =
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0
0 () α
(10)
with vnv nv
R
s
RX
s
X =+
55 44 being the total viral load and
vs
R5 and vs
X4 the viral load of one R5o rX4s t r a i n
respectively. The total viral load attributed to R5a n dX4
viruses can be derived to
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leading to equations (6) and (7) (v(n
R5, n
X4)=v
R5(n
R5,
n
X4)+v
X4(n
R5, n
X4)). Note that v
R5(n
R5, n
X4)<0
corresponds to the case in which no R5 viruses can co-
exist with X4 viruses, i.e. a total coreceptor switch [20].
In case of a reduction of the growth rate in R5 viruses
from r to rCCR5 <r the above equations change to
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leading to a condition for the onset of AIDS
n
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that allows for more virus strains and the condition for
dominance of X4 viruses becomes
n
rCCR cpX nR
rcpR kr r CCR qr r CCR nR
X4 5
45
5 2 55
5 >
++ − (( ) )
.
α
(14)
Note that less R5 viruses can coexist with X4 viruses in
case of rCCR5 <r, i.e. neither R5 infection nor X4 infection
(due to lack of immune activation) can progress as fast
as without therapy.
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Assuming fast equilibration of viral load relative to the
time scale of emergence of new mutants allows to model
the evolution in the number of viral strains as a Markov
process [35] with constant transmission rates between
states which are proportional to the equilibrium viral
load. With P(n
R5, n
X4, t) being the probability to find n
R5
R5 strains and n
X4 X4 strains at time t the master
equation [35] for this process can be written as
∂
∂
=− +− −
t
Pn n t
p v nn p v nn P n
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(15)
with p1 being the probability per time and viral load to
mutate within the same subtype (R5 ÆR5, X4 ÆX4) and p2
being the probability per time and viral load to mutate
betweensubtypes(R5ÆX4,X4ÆR5).Forthedatashownit
holdsp1=p2= 1
2 pm =0.0 05d
-1VL
-1(forp1≠p2cf.Additional
file 1, Figure S1). The last term in equation (15) vanishes if
the criticalnumberofstainsaccordingtoequation(3)orthe
maximal viral load vmax =5 0 0 VLis exceeded leading to an
absorbingboundary.ThetimeevolutionofP(n
R5,n
X4,t)wa s
solved numerically with routine rk4 from the Math::
RungeKutta module for PERL with the initial condition
P(1, 1, 0) = 1 (zero otherwise) corresponding to the
initialisation with one R5 and one X4s t r a i n .
ThedistributionofthewaitingtimestotheonsetofAIDSon
the basis of an initial distribution in strain numbers n
R5,
n
X4can be described by a phase type distribution [36]. With
p1 = p2 = 1
2 pm, a patient’s average residence time in a
configuration with n
R5 R5 virus strains and n
X4 X4 virus
strains is λnn
RX
pmvn R nX
54 1
54 , (,)
= i.e. decreasing with a
growing number of viral strains and in consequence viral
load v(n
R5, n
X4). This allows to derive the mean time to the
onset of AIDS in a patient with n
R5 R5 virus strains and n
X4
X4 virus strains to
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if equ    holds
else
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(16)
The mean waiting time until the onset of AIDS is derived
in equation (16) by averaging the waiting times arising
along all possible evolutionary paths starting form a
configuration with n
R5 R5 virus strains and n
X4 X4 virus
strains (cf. Additional file 5, Figure S5).
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Additional material
Additional file 1
Mutation between R5 and X4 viruses. The Figure shows a comparison
between the situation of homogeneous and heterogeneous mutation rates
among R5 and X4 viruses. While the former case (left panel) corresponds to
the situation discussed in the main paper, i.e. mutation rates being identical
among and between subtypes p1 =p 2 = , the latter case (right panel) has the
sametotalmutationratepm=0.01 d
-1VL
-1butathreefoldhigherprobability
for intra-subtype mutation than inter-subtype mutation, i.e. p1 =,p 2 = . The
top row shows how this assumption shifts evolutionary paths towards routes
with a higher fraction of R5 viruses. In consequence, X4 dominance is less
often attained before the onset of AIDS leading to a lower fraction of
coreceptor switches. This might however be shifted to the observed levels by a
stronger coupling of X4 growth to immune activation. The survival curves
decay slightly steeper in the case of heterogeneous mutation patterns because
moreviableR5mutants (than notyet adaptedX4mutants)aregenerated in
the earlier stages of disease. The exact mutation rates among R5 and X4
viruses are hard to estimate, but their sequence similarity suggests them to be
of a similar order of magnitude (p1 ≈ p2) [33].
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2148-9-274-S1.PDF]
Additional file 2
Equilibrium viral load. Viral load of R5 viruses (blue) and X4 viruses
(red) in a simulation of the model described by equations (1) as shown
in Fig. 1 (parameters as in table 2). In addition the equilibrium viral
load according to equations (11) is shown with good agreement with the
simulation data. Deviations occur only at the breakdown of the system
where no equilibration can be expected any more.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2148-9-274-S2.PDF]
Additional file 3
Variation of mutation rate pm. Survival distribution for pm = 0.01 (cf.
Fig. 4) and pm = 0.1 sampled from equations (1) (200 runs each) in
comparison with the probabilistic approach (5), other parameters as in
table 2. The ten-fold increase of mutation rate shrinks the time axis of
the survival distribution by a factor of 10. The survival curves for pm =
0.1 are still close but the sampled curve decays faster than predicted by
the master equation approach as mutants are already likely to be
established in the initial viral peak, i.e. do not allow for equilibration.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2148-9-274-S3.PDF]
Additional file 4
Suppression of R5 viruses and viral load. The density plots show the
equilibrium viral load determined by equations (11,12) (as visualised in
Additional file 2, Figure S2) depending on the numbers of R5 and X4
virus strains being present. The top row shows the equilibrium viral load
for R5 viruses v
R5(n
R5,n
X5)a n dX 5v i r u s e sv
X4(n
R5,n
X4) for parameter
values as depicted in Table 2. The bottom row shows the same situation,
however, with the growth rate of R5 viruses halved to 1d
-1 leading to a
situation in which hardly any R5 viral load can be established. This
however, results at the same time in a lower viral load from X4 viruses
(cf. right panel). In consequence, the model predicts an indirect positive
effect from the suppression by R5 viruses as induced by CCR5 blockers.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2148-9-274-S4.PDF]
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Mean waiting time to the onset of AIDS. The Figure shows a graphical
representation of equation (16) in the n
R5-n
X4-plane showing the
probability to find n
R5 R5 strains and n
X4 X4 strains in a patient at
1200 days since infection (cf. Fig. 2). The mean waiting time to the
onset of AIDS is determined by averaging the waiting times along all
possible evolutionary paths. Therefore, decreases with a growing number
of strains (here: T4,4 >T 6,5).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2148-9-274-S5.PDF]
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